Aim: A novel jelly lactulose preparation (SK-1202) has been developed to improve compliance and reduce the elevation of blood glucose levels in diabetic patients. To compare the equivalence in the efficacy and safety of SK-1202 and an approved commercially available syrup preparation, we undertook a randomized multicenter cross-over study in hyperammonemia patients with liver cirrhosis who were taking lactulose.
INTRODUCTION
L ACTULOSE SYRUP HAS been used for hyperammonemia and constipation for many years in many countries around the world. [1] [2] [3] According to the Japanese guidelines for hepatic cirrhosis, disaccharides such as a lactulose are recommended for patients with hepatic encephalopathy (evidence level, high; strength, strong recommendation). 4 However, one important issue associated with lactulose syrup is its excessively sweet taste, which ultimately influences patient compliance with treatment. An additional issue to consider is that the lactulose syrup, formulated in accordance with the Japanese Pharmacopoeia, US Pharmacopoeia, or European Pharmacopoeia, contains some free lactose and galactose, and thus, should be used with caution in patients with diabetes mellitus. In order to overcome the aforementioned concerns, we developed a novel lactulose preparation (SK-1202) that has appropriate palatability and contains less free sugar. We compared the efficacy, safety, and acceptability of SK-1202 with an approved currently available lactulose syrup by a crossover study.
METHODS

Study design
T HE STUDY SCHEDULE is shown in Figure 1 . Patients were screened on visits 1 and 2 during the observation period. Eligible subjects were randomized to either of two groups in turn according to an assignment list for each study site. The assignment lists were created using the SAS software program (SAS Institute, Cary, NC, USA.). In the first phase of the study, the patients in group A received the new preparation (SK-1202) and patients in group B received the approved lactulose syrup for 2 weeks, and in the subsequent step, the patients were crossed over to the alternative preparation for an additional 2 weeks of treatment.
Patients
This multicenter study enrolled patients from five hospitals in Japan: Sapporo-Kosei General Hospital, Toranomon Hospital, Toranomon Hospital Kajigaya, Nara Medical University Hospital, and Hiroshima University Hospital. Based on the previous clinical study of lactulose 5 and the number of subjects in which an adverse event with 10% incidence is detectable with a probability of 95%, a sample size of 40 subjects was planned. The main inclusion criteria were: (i) stable hyperammonemia with compensated liver cirrhosis; (ii) treatment with an approved lactulose product of 19.5-39 g t.i.d. for >4 weeks before the observation period; (iii) Inuyama coma score of I or no coma; and (iv) values of no more than 200% of blood ammonia measurements in two separate samples during the observation period, calculated by the normal upper limit value of the testing site (100%). The main exclusion criteria were: (i) changes in dosage of lactulose during the observation period and/or 4 weeks before the observation period; (ii) fulminant hepatitis and/or higher than grade C of the Child-Pugh classification; (iii) plan for endoscopic injection sclerotherapy or endoscopic variceal ligation for esophageal varix during the study period; (iv) plan to undergo new treatment for malignant tumor during the observation period or 4 weeks prior, and/or planned new treatment during the study period; (v) severe renal impairment or serum creatinine ≥1.7 mg/dL (men) or ≥1.3 mg/dL (women) at the start of the observation period; (vi) dementia; (vii) severe heart disease or heart attack 26 weeks before the observation period; (viii) severe gastrointestinal disorders; (ix) galactosemia; and (x) hyperammonemia with inborn errors of metabolism. Informed written consent to participate in this study was obtained from all patients. This study was approved by the ethics committee of each institution and was carried out in compliance with the Declaration of Helsinki and Good Clinical Practice Guidelines.
Preparation and dosage
SK-1202 is produced by Sanwa Kagaku Kenkyusho Co., Ltd. (Nagoya, Japan). The active pharmaceutical ingredient in this preparation is crystal lactulose with a purity of >97%. This preparation is in gel form and contains 6.5 g lactulose in a sachet. Lactulose syrup (Monilac; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) containing 6.5 g/10 mL lactulose in a sachet was launched in Japan in 1975.
The patients took SK-1202 or lactulose syrup three times daily containing the same amount of lactulose taken in the observation period.
Efficacy and safety evaluation
Efficacy was evaluated by the number connection test (NCT), concentration of blood ammonia, coma grade, and flapping tremor grade at visits 3, 4, and 5. The NCT was measured using Neuro-Psychological Tests provided by The Japan Society of Hepatology. 6 Fasting blood ammonia levels were measured at the participating sites and Figure 1 Design of a randomized, multicenter, cross-over study to compare SK-1202 and an approved commercially available lactulose syrup in hyperammonemia patients with liver cirrhosis. the values were adjusted according to the upper limit values of each site. Data were calculated to a percent value against the upper limit value of each institution. The coma grade was evaluated using the six levels of the Inuyama coma scale (no coma and grades I-V). 7 The flapping tremor grade was evaluated according to four levels: 0, no tremor; 1, unclear; 2, present; and 3, clearly present. Safety was determined based on the presence of adverse events, changes in vital signs, and laboratory tests, which included hematological tests, biochemical blood tests, coagulation tests, and urine tests.
Acceptability evaluation
The acceptability of the preparation was evaluated at visits 4 and 5 by questionnaire on the sweetness, aftertaste, ease of administration, and preference of the preparation. The questions consisted of four levels of sweetness (good, slightly sweet, very sweet, too sweet), aftertaste (not unpleasant, slightly unpleasant, unpleasant, very unpleasant), and ease of administration (excellent, easy, difficult, very difficult). The question regarding preference involved selection of the preferred preparation.
Statistical analysis
Continuous data were evaluated using ANOVA, and the ordered data were evaluated using the Wilcoxon rank sum test, Wilcoxon signed-rank test, or sign test.
RESULTS
Patients
F
ORTY-SIX SUBJECTS WERE screened; of which two subjects were ineligible because of conflicts with the inclusion or exclusion criteria. Overall, 44 subjects were registered in this study. Demographic data are shown in Table 1 . Twenty-six subjects were men (59.1%) and the mean age was 65.4 years. The main cause of hyperammonemia was alcohol consumption, with a ratio of >50%. The coma grade for all subjects was <I. Forty-four subjects were randomized to two groups, group A or B. Twenty-four subjects in group A were dosed with lactulose syrup and 20 subjects in group B were dosed with SK-1202 for the first 2 weeks, and then they were crossed over to the alternative preparation for another 2 weeks. Only one subject in group A withdrew at the end of the first treatment period (lactulose syrup) at the subject's request. The remaining subjects completed the study. The number of subjects for the evaluation of SK-1202 or lactulose syrup was 43 and 44, respectively.
Efficacy
The NCT results are shown in Figure 2 [CI] . À5.84, 3.54). The changes in blood ammonia (%) levels were À12.49 ± 54.78 (mean ± SD) during the SK-1202 treatment period and 8.13 ± 54.47 (mean ± SD) during the lactulose syrup treatment period, as shown in Figure 2(b) . The results of ANOVA showed there was no difference between the preparations (differences of conditioned mean, À22.18; 95% CI, À51.76, 7.39).
Only one subject in group B had grade I coma at visit 3 and the coma grade of this subject changed from I to no coma following SK-1202 treatment.
Only two subjects in group B had grade 1 (unclear) flapping tremor at visit 3 and the tremor grade of these subjects changed from 1 to 0 (no tremor) after SK-1202 treatment.
Safety
Eight adverse events were observed in six patients (14.0%) during the SK-1202 treatment period and included four cases of diarrhea in two patients (4.7%). Nine adverse events were observed in six patients (13.6%) during the lactulose syrup treatment period and included five cases of diarrhea in three patients (6.8%). Diarrhea was considered an adverse reaction. No other adverse events were considered adverse reactions. Among all the adverse events observed, one case of mycoplasma pneumonia in the lactulose syrup treatment period was the only serious adverse event. No significant changes were observed in vital signs or laboratory tests.
